Scientists in the U.K. have used genome mining to identify bacterial species capable of producing novel polyene antifungal compounds that are both more effective and have a more benign side effect profile than approved polyenes such as amphotericin and nystatin. Read More

Researchers from Yunnan University, Sicagene Bioscience Co. Ltd. and collaborators reported the preclinical efficacy of GS-10c, a GalNAc-conjugated antisense oligonucleotide (ASO) developed to silence serine/threonine kinase 25 (STK25), a lipid droplet-associated kinase implicated in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Read More

Create Medicines Inc. has received Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human study of CRT-402, the company’s lead in vivo CAR T candidate for the treatment of autoimmune diseases. Read More

Olix Pharmaceuticals Inc. has released preclinical data from a head-to-head study in obese nonhuman primates (NHPs) showing that OLX-501A, its ALK7-targeting obesity program, achieved greater visceral fat reduction relative to a globally developed comparator compound. Read More

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of cancer, autoimmune and metabolic disease, eye, dermatological, respiratory, cardiovascular and renal disorders, among others. Read More

Kaigene Inc. has entered into a licensing agreement with Taisho Pharmaceutical Co. Ltd. for the exclusive development and commercialization of Kaigene’s next-generation human neonatal Fc receptor (FcRn) inhibitor, KG-006, in Japan. Read More

University of Miami and Starx Therapeutics Inc. have presented data on UMF-814A, a STK17A inhibitor with promising activity in myelodysplastic syndrome and acute myeloid leukemia. Read More

Sunrock Biopharma SL has disclosed antibody-drug conjugates (ADCs) comprising an antibody targeting C-C chemokine receptor type 9 (CCR9) linked to camptothecin derivatives through a linker found to be potentially useful for the treatment of cancer. Read More

Tahrget Therapeutics Ltd. has patented substituted adefovir compounds acting as viral DNA polymerase inhibitors that are potentially useful for the treatment of Epstein-Barr virus infections. Read More

TSC Alliance and Apertura Gene Therapy LLC have announced progress in their collaboration to advance gene therapies to treat tuberous sclerosis complex (TSC) with the completion of a preclinical pilot study evaluating an AAV gene therapy approach for TSC1. Read More

Apex Bioscience Inc. has presented phosphodiesterase PDE4 and cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A; PDE5) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease (COPD), heart failure, hepatic fibrosis, inflammatory bowel disease, rheumatoid arthritis, idiopathic pulmonary fibrosis and Alzheimer’s disease, among others. Read More

Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s disease, diabetic neuropathy, glaucoma, viral infections, chemotherapy-induced peripheral neuropathy and stroke, among others. Read More

Mira Pharmaceuticals Inc. has reported continued progress toward IND-enabling studies of its two lead preclinical programs, MIRA-55, an investigational oral nonopioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders. Read More